跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

B8063

Sigma-Aldrich

BML-210

≥98% (HPLC), powder

同義詞:

N1-(2-aminophenyl)-N8-phenyl-octanediamide

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C20H25N3O2
CAS號碼:
537034-17-6
分子量：:
339.43
MDL號碼:
MFCD08062139
分類程式碼代碼:
12352200
PubChem物質ID:
329773304
NACRES:
NA.77
暫時無法取得訂價和供貨情況

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to very faintly yellow

溶解度

DMSO: >20 mg/mL

儲存溫度

2-8°C

SMILES 字串

Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2

InChI

1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)

InChI 密鑰

RFLHBLWLFUFFDZ-UHFFFAOYSA-N

生化／生理作用

BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM.
BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia.[1] In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis.[2] BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.[3]
BML-210 is an HDAC inhibitor.

特點和優勢

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

危險聲明

H413

防範說明

P273 - P501

危險分類

Aquatic Chronic 4

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
0000185793
0000185792
0000185793
0000185792
021M4616V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Veronika Borutinskaitė et al.
International journal of molecular sciences, 16(8), 18252-18269 (2015-08-20)
Today, cancer is understood as an epigenetic as well as genetic disease. The main epigenetic hallmarks of the cancer cell are DNA methylation and histone modifications. Proteins such as histone deacetylases (HDACs) that cause modifications of histones and other proteins
The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines
Savickiene J, et al.
European Journal of Pharmacology, 549(1-3), 9-18 (2006)
Natalia Sacilotto et al.
Genes & development, 30(20), 2297-2309 (2016-11-30)
Angiogenesis, the fundamental process by which new blood vessels form from existing ones, depends on precise spatial and temporal gene expression within specific compartments of the endothelium. However, the molecular links between proangiogenic signals and downstream gene expression remain unclear.
The histone deacetylase inhibitor BML-210 influences gene and protein expression in human promyelocytic leukemia NB4 cells via epigenetic reprogramming
Borutinskaite V and Navakauskiene R
International Journal of Molecular Sciences, 16(8), 18252-18269 (2015)
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
Jayathilaka N, et al.
Nucleic Acids Research, 40(12), 5378-5388 (2012)
查看所有相關論文

文章

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

發現基因調控的生物活性小分子

我們提供各種小分子研究工具，例如轉錄因子調節劑、染色質修飾酵素的抑制劑，以及用於基因調控研究中靶點鑑定和驗證的激效劑/拮抗劑；以下是這些研究工具的精選。

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務